Accurate Quantification of Choline-to-Creatine Ratio as a Biomarker to Distinguish Osteosarcoma Patients from Normal Subjects Employing Proton Magnetic Resonance Spectroscopy Imaging at 3 Tesla

Shaghayegh Karimi Alavijeh; Fakhereh Pashaei; Mahrooz Malek; Hamidreza Saligheh Rad

doi:10.18502/fbt.v8i2.6513

Accurate Quantification of Choline-to-Creatine Ratio as a Biomarker to Distinguish Osteosarcoma Patients from Normal Subjects Employing Proton Magnetic Resonance Spectroscopy Imaging at 3 Tesla

Shaghayegh Karimi Alavijeh

Fakhereh Pashaei

Mahrooz Malek

Hamidreza Saligheh Rad

Abstract

Purpose: This study focused on accurate quantification of a maximum of Choline-to-Creatine ratio (Max (Cho/Cr)) in 10 Osteosarcoma patients, in comparison with 5 healthy volunteers as our control group using proton Magnetic Resonance Spectroscopy Imaging (1H-MRSI).

Materials and Methods: Max (Cho/Cr) were obtained in 10 patients with Osteosarcoma over their corresponding ratio maps containing diseased tissue, to be compared with Cho/Cr in 5 healthy volunteers at 3T, employing MRSI (Performed Employing Pointed-resolved Spectroscopy (PRESS), TR/TE: 2500s /135 ms) with water-suppression. An extra unsuppressed water Single-Voxel Spectroscopy (SVS) was acquired to provide phase information for further Eddy Current Correction (ECC). Multi-stage preprocessing was applied. Subtract QUEST MRSI as a time-domain technique was employed to accurately quantify the metabolites’ ratios and to estimate the baseline.

Results: An optimal database for Subtract QUEST was achieved based on multiple trials evaluated by acceptable peak-fitting and Cramer-Rao-Bound (CRB). Lipids at frequencies of 0.94 and 1.33ppm were combined to increase the accuracy of the Lipid estimation.

Conclusion: Estimation of Max (Cho/Cr) evaluated over Cho/Cr spatial maps to distinguish Osteosarcoma patients from normal subjects suggested that the proposed quantification method leads to high power and linear classifier with a high degree of reproducibility, considering 1H-MRSI at 3T machine as a high efficacy diagnostic tool for musculoskeletal radiology.

1- Ċ. Carlsson, “Susceptibility effects in MRI and 1H MRS. The spurious echo artifact and susceptibility measurements.” Department of Physics; Institutionen för fysik, 2009.
2- J. B. Lambert and E. P. Mazzola, "Nuclear Magnetic Resonance Spectroscopy An Introduction to Principles, Applications and Experimental Methods (paper)," Recherche, vol. 67, p. 02, 2003.
3- P. K. Mandal, "< i> In vivo proton magnetic resonance spectroscopic signal processing for the absolute quantitation of brain metabolites," European journal of radiology, vol. 81, no. 4, pp. e653-e664, 2012.
4- I. C. Smith and L. C. Stewart, "Magnetic resonance spectroscopy in medicine: clinical impact," Progress in Nuclear Magnetic Resonance Spectroscopy, vol. 40, no. 1, pp. 1-34, 2002.
5- R. E. Jung, C. Gasparovic, R. S. Chavez, A. Caprihan, R. Barrow, and R. A. Yeo, "Imaging intelligence with proton magnetic resonance spectroscopy," Intelligence, vol. 37, no. 2, pp. 192-198, 2009.
6- A. K. Singh, A.-M. Wang, and W. Sanders, "Magnetic resonance spectroscopy of the brain," APPLIED RADIOLOGY, vol. 31, no. 12; SUPP/2, pp. 58-65, 2002.
7- A. Di Costanzo et al., "Proton MR spectroscopy of the brain at 3 T: an update," European radiology, vol. 17, no. 7, pp. 1651-1662, 2007.
8- P. Stanwell and C. Mountford, "In Vivo Proton MR Spectroscopy of the Breast1," Radiographics, vol. 27, no. suppl 1, pp. S253-S266, 2007.
9- P. J. Bolan, M. T. Nelson, D. Yee, and M. Garwood, "Imaging in breast cancer: magnetic resonance spectroscopy," Breast Cancer Res, vol. 7, no. 4, pp. 149-152, 2005.
10- F. G. Claus, H. Hricak, and R. R. Hattery, "Pretreatment Evaluation of Prostate Cancer: Role of MR Imaging and 1H MR Spectroscopy1," Radiographics, vol. 24, no. suppl 1, pp. S167-S180, 2004.
11- R. Kumar, M. Kumar, N. Jagannathan, N. P. Gupta, and A. K. Hemal, "Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate," Urological research, vol. 32, no. 1, pp. 36-40, 2004.
12- A. Qayyum, "MR spectroscopy of the liver: principles and clinical applications," Radiographics, vol. 29, no. 6, pp. 1653-1664, 2009.
13- S. Doganay, T. Altinok, A. Alkan, B. Kahraman, and H. M. Karakas, "The role of MRS in the differentiation of benign and malignant soft tissue and bone tumors," European journal of radiology, vol. 79, no. 2, pp. e33-e37, 2011.
14- C.-K. Wang, C.-W. Li, T.-J. Hsieh, S.-H. Chien, G.-C. Liu, and K.-B. Tsai, "Characterization of Bone and Soft-Tissue Tumors with in Vivo 1H MR Spectroscopy: Initial Results1," Radiology, vol. 232, no. 2, pp. 599-605, 2004.
15- L. M. Fayad, D. A. Bluemke, E. F. McCarthy, K. L. Weber, P. B. Barker, and M. A. Jacobs, "Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization," Journal of Magnetic Resonance Imaging, vol. 23, no. 1, pp. 23-28, 2006.
16- L. M. Fayad et al., "Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy," American Journal of Roentgenology, vol. 188, no. 6, pp. 1513-1520, 2007.
17- Z.-h. Qi, C.-f. Li, Z.-f. Li, K. Zhang, Q. Wang, and D.-x. Yu, "Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors," Chinese Medical Journal (English Edition), vol. 122, no. 1, p. 39, 2009.
18- C. W. Lee et al., "Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification," Clinical imaging, vol. 34, no. 1, pp. 47-52, 2010.
19- L. M. Fayad et al., "Quantification of Muscle Choline Concentration by Proton MR Spectroscopy at 3 Tesla: Technical Feasibility," AJR. American journal of roentgenology, vol. 194, no. 1, p. W73, 2010.
20- D. S. Geller and R. Gorlick, "Osteosarcoma: a review of diagnosis, management, and treatment strategies," Clinical advances in hematology & oncology: H&O, vol. 8, no. 10, p. 705, 2010.
21- M. J. Klein and G. P. Siegal, "Osteosarcoma anatomic and histologic variants," American journal of clinical pathology, vol. 125, no. 4, pp. 555-581, 2006.
22- H. Ratiney, M. Sdika, Y. Coenradie, S. Cavassila, D. v. Ormondt, and D. Graveron‐Demilly, "Time‐domain semi‐parametric estimation based on a metabolite basis set," NMR in Biomedicine, vol. 18, no. 1, pp. 1-13, 2005.
23- D. Graverondemilly, A. Diop, A. Briguet, and B. Fenet, "Product-operator algebra for strongly coupled spin systems," Journal of Magnetic Resonance, Series A, vol. 101, no. 3, pp. 233-239, 1993.
24- F. Jiru, "Introduction to post-processing techniques," European journal of radiology, vol. 67, no. 2, pp. 202-217, 2008.
25- A. Bizzi, N. De Stefano, R. Gullapalli, and D. D. Lin, “Clinical MR spectroscopy: techniques and applications.” Cambridge University Press, 2010.
26- Karimi Alavijeh Sh, Madadi A, Oghabian MA, Malek M, Salighe Rad HR “Accurate quantification of Cho/Cr in Osteosarcoma employing clinical 1H-MRSI at 3T; a comparison study with normal tissue.” In: Proceedings of the 30th scientific meeting, European Society for Magnetic Resonance in Medicine and Biology, France, p, 2013.

Files	XML pdf (679KB)
Issue	Vol 8 No 2 (2021)
Section	Original Article(s)
DOI	https://doi.org/10.18502/fbt.v8i2.6513
Keywords
Magnetic Resonance Spectroscopy Magnetic Resonance Spectroscopy Imaging Metabolite Osteosarcoma Subtract Quantum Estimation

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Karimi Alavijeh S, Pashaei F, Malek M, Saligheh Rad H. Accurate Quantification of Choline-to-Creatine Ratio as a Biomarker to Distinguish Osteosarcoma Patients from Normal Subjects Employing Proton Magnetic Resonance Spectroscopy Imaging at 3 Tesla. Frontiers Biomed Technol. 2021;8(2):94-101.

Vancouver

Download Citation